Redesigning TRACER trial after TRITON

Serebruany, Victor L.

doi:10.1016/j.ijcard.2015.06.020

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2017

Publication Types

Select...

Article5

Relationship

Self Cite1

Independent4

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The “good news” is that vorapaxar per se can be most definitely exonerated from the harm observed for stroke prevention, and especially from alarming ICH numbers. 14 The bad news is that vorapaxar has been approved in May 2014, but it’s clinical utilization is still very low, or even not existing in many remote from US markets. It seems that despite the heavy expense of investing in two mega trials, it is challenging to test vorapaxar as a monotherapy in another head-to-head stroke prevention study against clopidogrel and extended-released dipyridamole.…”

Section: Discussionmentioning

confidence: 99%